A Clinical trial to study the effects and tolerability of Dacne gel containing Clindamycin Phosphate 1% and zinc acetate in patients suffering from acne.
Phase 4
Completed
- Conditions
- Health Condition 1: null- mild to moderate inflammatory acne
- Registration Number
- CTRI/2011/091/000041
- Lead Sponsor
- Glenmark Pharmaceuticals Ltd
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 125
Inclusion Criteria
?Subjects with mild to moderate inflammatory acne with comedones, papules or pustules predominate (Grade 1 and grade 2, IADVL acne grading system) affecting face
?Subjects must be 18-40 years of age
?Subjects must provide written informed consent and comply to the protocol
Exclusion Criteria
?Subjects not willing to discontinue all topical treatments for Acne for 2 weeks prior to enrollment in study
?Hypersensitivity to any ingredients of D?acne
?Pregnant and lactating women.
?Subjects taking Concomitant therapy that might interfere with the study results in the investigator?s opinion.
?Subjects with dermatological disorder of face that may interfere with study evaluation.
Study & Design
- Study Type
- PMS
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method